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1. Introduction 
1.1 Breast cancer 
 
1.1.1.  Incidence and mortality 
Breast cancer is the most common cause of cancer among women, accounting for over 
one-fifth of the estimated annual 4.7 million cancer diagnoses in females, and the 
second most common tumour, after lung cancer, in both sexes (1). There is at least a 
10-fold variation in worldwide breast cancer incidence rates as a consequence of a 
range of socio-economically differences in the population prevalence of several factors 
such as reproduction, hormons and nutrition (2). The highest incidence rates occur in 
northern and western Europe, northern America, Australia and New Zealand, and in 
southern countries of South America. Also screening programmes, such as that 
introduced in several European countries in the late 1980s, influence trends in the 
incidence and mortality of breast cancer. In some countries mortality started 
decreasing before screening was introduced, but its decline also occurred in non-
screened age groups, and in some countries without national screening programmes 
suggesting that the major factors of the observed tendencies vary among the countries, 
and may include earlier detection by screening, but also improvements in therapy (3). 
Mortality has increased from the 1950s until at least the 1980s in most European 
countries, particularly in East and South Europe and from the early 1990s there was an 
evident decline which has affected women aged less than 50 years. The pattern 
observed in the USA and Canada is broadly similar to that of Europe, with comparable 
increases in incidence in both white and black women (4). Similarly to Europe, a 
decline in mortality took place in 1980s, and from 1992 to 2000 breast cancer death 
rates among white women declined in 38 US states, whereas among blacks increases 
were observed in several states (5). Breast cancer incidence has a distinctive age-
specific curve (Fig. 1): there is a rapid rate of increase before the menopause (age 40-
50) that slows down after it probably due to diminishing levels of circulating 
oestrogens. Overall, breast cancer incidence rates increased during the most recent 
time period (2006-2010) among non-Hispanic white women aged 30 years to 49 years, 
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and African American women aged 60 years to 69 years, whereas rates decreased for 
Hispanic women aged 30 to 49, and 50 years to 59 years. Trends by ER (Estrogen 
Receptor) status were also estimated: overall there was a decrease in ER- tumors and 
an increase in ER+ tumors. During 2006 to 2010, the incidence rates of ER+ breast 
cancer increased in African American women with faster intensification among 
younger groups. Rates of ER+ breast cancer also grew among younger (30 years to 49 
years) white women and Hispanic women aged 60 to 69 years, while significant 
decreases were observed for ER- breast cancer in most age/racial/ethnic groups (6). 
 
 
Fig.1: Age-specific breast cancer incidence rates in selected cancer registries 
 
1.1.2.  Risk factors 
There are several risk factors linked to breast cancer: age, reproductive factors, 
personal or family history of breast disease, genetic pre-disposition, and environment. 
Age increases the risk of developing breast cancer in fact, in the United States, the 
probability of a woman developing breast cancer increases with age, from 0.5% up to 
39 years, at 3.78% after 40 years (7). Initial DCIS or stage IIB, estrogen/progesterone 
receptor-negative, and age <50 years are all factors associated with higher recurrence 
and second primary rates. Women with a family history or greater breast density had 
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higher second primary rates, and women who received breast conserving surgery 
without radiation had higher recurrence rates. These evidences identify subgroups 
who may benefit from increased surveillance (8). Some proliferative breast lesions 
including usual ductal hyperplasia, intraductal papillomas, sclerosing adenosis and 
fibroadenomas confer a small increased risk of breast cancer development, while 
women with atypia have an approximately 4.3 fold greater risk of developing it, if 
compared to the general population (9). The risk increases in case of family history: 
women who have one, two or three affected first degree relatives have risk ratios of 
1.80, 2.93 and 3.90 respectively, compared with women who have no affected relative 
(10). A genetic predisposition identified mutations in the genes BRCA1 and 2 is 
considered another predisposing factor to the onset of breast cancer as lifetime breast 
cancer risk ranges from 65% to 85% for BRCA1 mutation carriers and 45% to 85% for 
BRCA2 carriers. Other genes including homozygous ataxia-telangiectasia (ATM), 
CHEK2, BRIP1 and PALB2, confer a 20%-40% lifetime risk (11,12). Among the risks 
can be further listed endogenous hormone exposure, reproductive factors, and 
exogenous hormone exposure ones. The first ones can be associated with: an early 
menarche (13), the fact that nulliparous women are at an increased risk compared to 
parous women (14), breast feeding as a protective role (15), high endogenous sex 
hormone levels (16) and later onset at menopause (17). Evidences suggest also a 
relationship between the use of hormone replacement therapy (HRT) and breast 
cancer risk (18). 
 
1.1.3.  Molecular subtypes 
Breast cancer studies has revealed substantial tumor heterogeneity consisting of 
different molecular subtypes, with distinct clinical and biological characteristics (19). 
In the recent years, molecular profiling of breast cancer by gene expression studies has 
provided important tool to discriminate different subtypes, each associated with 
clinical outcome and treatment response. Based on the molecular studies, breast 
carcinomas can be classified in main groups. 
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1.1.3.1   Luminal A and B subtypes 
Luminal A subtype represents 50-60% of breast cancers and is the most common one. 
This subtype includes overexpression of genes related to cells of the luminal side of 
mammary ducts, estrogen receptor (ER) and ER transcription factors (20). The 
histological and IHC classification includes low histological grade, low Ki67 index, 
positive staining for ER, progesterone receptor (PgR) and luminal epithelial markers 
like cytokeratin (CK) 8 and 18. This subtype has the lowest rate of TP53 mutation. 
Luminal A is the subtype that shows the best prognosis with a 5-year survival rate of 
90 % for patients with primary breast cancer (21), and generally is associated with less 
lymph nodes involvement, lower local and distant recurrent rates (22). Luminal B 
subtype varies from 10 to 30% and shares histological similarities with luminal A, only 
changing an higher Ki-67 index and a moderate histological grade (23). Currently, 
luminal B carcinomas are divided into luminal B/Her2-negative and luminal B/Her2-
positive subgroups. 
 
1.1.3.2  Her2-positive subtype 
Her2-enriched subtype represents the 4-7% of breast carcinomas and is characterized 
by amplification, or overexpression of Her2 oncogene and genes located at the Her2 
amplicon on chromosome 17q22.24. IHC and histological features include Her2 
overexpression, negative staining for ER and PgR and high histological grade. It differs 
from luminal subtype because of the high incidence of advanced disease at the time of 
diagnosis, an increased risk of metastasis usually to brain, lung and liver, and a short 
overall survival (24). 
 
1.1.3.3  Basal-like subtype 
Basal-like subtype represents 10-20 % of breast cancers (21) and is characterized by 
overexpression of some genes associated to cells of  the basal layer of mammary ducts, 
such as CK5/6, CK17, laminin, integrin b4, EGFR and fatty acid binding protein 7 
(19,20). It usually shows a high Ki-67 index and high histological grade and IHC and it 
is positive for CK5/6 and CK17 staining. Although this subtype is characterized by the 
lack of expression of ER and PgR, as well as Her2 overexpression there are some 
differences between it and triple negative breast cancers (TNBCs). However, they 
largely overlap in 70-80 % of cases referring to morphology (ductal carcinoma of high 
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histological grade), association with BRCA1 mutations and lack of benefit from 
endocrine or Her2-based therapy. 
 
1.1.3.4  Triple negative subtypes 
Triple negative breast cancers (TNBCs) collect several subgroups of breast carcinomas 
characterized by different clinical, histological, immunoistochemical and pathological 
features. Their main feature is the lacking of ER, PgR and Her-2 expression, the reason 
why patients are insensitive to most currently ER-targeted, Her-2-based and hormonal 
therapies. This type of carcinoma affects 20-30% of all breast cancer patients and is 
more prevalent among young Latino, African and African-American women (25). More 
than 80% of BRCA-1 mutations are linked to triple negative groups and 20% of BRCA-1 
and BRCA-2 mutations show deficiency in DNA repair mechanisms. TNBCs are highly 
malignant, poorly differentiated, more aggressive, and show a poor outcome (26). 
Furthermore, patients with TNBCs have twice as likely than other women to develop 
distant metastasis, showing a shorter survival. Recently, Lehmann et al. have analyzed 
gene expression profiles from breast cancer data sets and identified 587 TNBC cases. 
Cluster analysis identified 6 TNBC subtypes including basal-like 1 and basal-like 2 (BL1 
and BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL), 
and a luminal androgen-receptor (LAR) subtype (27). The BL1 subtype is enriched in 
genes implicated in cell cycle, DNA replication, G2 cell-cycle pathway, RNA polymerase 
and G1 to S cell cycle (MYC, NRAS, PLK1, PRC1, TTK, CCNA2, AURKA, AURKB, CENPA, 
CENPF, BUB1, BIRC5). Furthermore, this subtype show a high Ki-67 mRNA expression 
and Ki-67 nuclear staining related to the high proliferative nature of the carcinoma. 
The BL2 subtype displays unique gene ontologies involving growth factor signalling 
(NGF, EGF, MET, Wnt/β-catenin and IGF1R pathways). The IM subtype is linked to 
immune cell processes, including immune cell signaling pathways (TH1/TH2, NK, B cell 
receptor signalling, T cell receptor signalling pathways), cytokine signaling (IL-12/17 
and cytokine pathways) and immune signal transduction pathways (NFkB, TNF and 
JAK/STAT signalling). The M subtype is characterized by high expression of genes 
involved in cell motility and cell differentiation pathway (Wnt and TGF-β signalling). 
The MLS group is enriched in genes related to angiogenesis (TEK1, TIE1, EPAS1 and 
VEGFR2). In addition, MLS expresses low levels of proliferation genes in comparison to 
ML one. The LAR subtype is an ER-negative subgroup that show a high percentage of 
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genes linked to hormonally regulated pathways, such as steroid synthesis or 
androgen/estrogen metabolisms. It shows high androgen receptor (AR) mRNA 
expression, more than all other subtypes, and it is heavily positive for nuclear AR 
staining (27).  
 
 
Fig. 2  Subdivision of triple negative breast cancer cell lines into different subtypes (Lehmann et al., J Clin 
Invest. 2011) 
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Fig. 3 Outcome of node negative women no adjuvant therapy based on genetic profile 
 
1.1.4. Current treatment strategies 
Being breast cancer a heterogeneous disease, characterized by several biological 
features, it is important to consider different clinical response patterns according to 
various treatment modalities and clinical outcomes. Today, biological characteristics 
such as tumor size, histological grade, patient’s age, ER, PgR, Her2 status and lymph 
node involvement are not more sufficient to evaluate patient-tailored treatment 
strategies. Therefore, recent studies of global gene expression (GEP) have provided 
evidences to open a broad field in cancer research to study new potential targets, 
allowing to improve patient risk stratification and to ensure the highest chance of 
benefit and the least toxicity from treatments. In particular, adjuvant therapy, 
including chemotherapy, hormonal therapy, human epidermal growth factor receptor 
(HER2)–directed and radiation therapies, supports surgery in effecting cure of breast 
cancer. 
 
1.1.4.1 Traditional and new chemotherapy 
Endocrine Therapy (ET) is the first choice treatment in the management of estrogen 
receptor alpha (ER )-positive breast cancer and it is used pre-operatively 
(neoadjuvant), post-operatively (adjuvant), and in the metastatic/advanced disease 
setting (palliative treatment). Current ET is constituted by treatments which modulate 
or disrupt the process of estrogen production or the function or presence of the ER in 
breast cancer cells. In pre-menopausal women estrogen production is largely due to 
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ovarian follicles under the control of the anterior pituitary gland which produces 
luteinizing hormone (LH), and follicle stimulating hormone (FSH). In postmenopausal 
ones, estrogens are dependent on peripheral aromatisation, predominantly in the liver, 
adrenal glands, and adipose tissue. Then, estrogen exerts its effect binding to ER wich 
regulates target genes transcription.  
 
1.1.4.2 Adjuvant cytotoxic chemotherapy and endocrine therapy in 
hormone receptor positive breast cancer 
Currently, there are two major types of strategies available for hormone receptor 
positive breast cancers: cytotoxic chemotherapy and endocrine therapy. Several 
studies have shown the improvement of patients disease free survival (DFS) and 
overall survival (OS). Among several regimens, the most widely used is CMF 
(cyclophosphamide, methotrexate and fluorouracil). It was first introduced by 
Bonadonna et al., (28), then several studies were carried out, including a meta-analysis 
showing a reduction of 6.2% in breast cancer related mortality after 10 years of follow 
up (29). Other important agents for adjuvant therapy are anthracyclines, among which 
the most used is Doxorubicin (Adriamycin) in stage II breast cancer patients. In 
particular, it has been reported it is effective in metastatic phase (30). Another 
important step in the chemotherapy has been the introduction of taxanes. Several 
clinical trials were performed, including a trial comparing sequential doxorubicin and 
docetaxel chemotherapy for lymph node positive breast cancer showing the 
superiority of doxorubicin in survival (31). 
The hormone therapy is divided into two drugs categories: selective estrogen receptor 
modulators (SERMs) and aromatase inhibitors (AIs). SERMs bind to estrogen receptors 
in a competitive way and they interfere with DNA synthesis by recruiting co-repressors 
and inhibiting cell cycle progression. Among SERMs, Tamoxifen has recently been the 
gold standard for the treatment of ER positive breast cancer in both pre- and post-
menopausal women. In 2011, the Early Breast Cancer Trialists’ Collaborative Group 
reported that 5 years of tamoxifen treatment reduced recurrence rates and mortality 
(32), but it has been shown that only with ER levels of 10 fmol/mg of cytosol protein or 
above there was tamoxifen efficacy and benefit, representing a limit in the use of this 
kind of treatment. Furthermore, in the last years a series of causes of acquired 
resistance to tamoxifen have been identified: the reduction or loss of ER signalling, the 
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recent discovered of G protein-coupled estrogen receptor 1 (GPER or GPR30), changes 
in ER-related co-factors, overexpression of Epidermal Growth Factor Receptor (EGFR) 
remain a problem and contribute to the development of endocrine-resistance. 
AIs act inhibiting the “aromatase” enzyme that converts circulating testosterone to 
estradiol (E2), and androstenedione to estrone, by aromatization. These pathways 
represents the main source of estrogen in post-menopausal women, for this reason AIs 
can act only if the primary source of estrogen is not available. The most common drugs 
of AI category are Anastazole, Letrozole and Exemestane, luteinizing-hormone-
releasing hormone (LHRH) agonists depriving estrogens.  
 
 
1.1.4.3 Adjuvant therapy in Her2 enriched breast cancer 
Trastuzumab is the first monoclonal antibody developed to target HER2 
transmembrane glycoprotein. It binds to the juxtamembrane domain of HER2 receptor 
leading to activation of p21 or p27 and transcription inhibition. It was approved in 
1997 by the first US Food and Drug Administration (FDA) and has become the first-line 
treatment in any stage of HER2-enriched disease. However, resistance to Trastuzumab 
therapy still represents a pivotal issue in the treatment of HER2 overexpressing 
carcinoma, and this is mainly due to defective apoptosis pathways (33). TD-M1 
(emtansine-trastuzumab conjugate) and Pertuzumab are newer agents targeting HER2 
and are currently approved by the US FDA for the use in metastatic stage (34). In 
particular, the antibody-drug conjugate T-DM1 has cytotoxic activity due to the 
microtubule-inhibitory agent DM1, leading to an improvement in patient OS. 
Lapatinib, another drug that binds to intracellular domain of HER2 protein, was the 
first small molecule developed to overcome Trastuzumab resistance. It has shown 
efficacy as a single agent or in combination with trastuzumab in metastatic setting. 
(35). 
 
1.1.4.4 Adjuvant therapy for triple negative breast cancer 
Since this tumor subtype lacks of effective molecular targets, chemotherapy remains 
the mainstay of adjuvant treatment. The platinum agents, Cisplatin and Carboplatin, 
have shown their DNA-damaging activity particularly in the triple-negative subgroup. 
Most part of basal-like subtypes associated to BRCA-1 mutations is sensitive to DNA-
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damaging agents because of impaired repair by homologous recombination of double-
strand breaks (DSB) induced by platinums, so these agents have become the best 
regimen in the metastatic stage (36). Anyway, standard treatments currently used in 
TNBC are the same as for hormone receptor positive carcinomas, whereas this group is 
sensitive to both anthracycline or taxane based regimen. Bevacizumab, an agent which 
targets the Vascular Endothelial Growth Factor (VEGF), is effective in TNBC, and 
clinical studies revealed the importance of angiogenesis and microenvironment in 
TNBC cells (37). TNBC is clearly a complex disease, and its impressive heterogeneity 
adds to the challenge of identifying targets and treatments. The focus will need to be on 
clinical trials of increasingly smaller subsets of TNBC patients, defined by molecular 
and genetic characteristics that classify a patient’s tumor into a subtype (i.e., receptor 
expression or mutation). 
 
 
Fig. 4 Distribution of triple-negative breast cancer (TNBC) subtypes from The Cancer Genome Atlas with enriched 
gene ontology and potential therapeutic targets. BL1, basal-like subtype 1; BL2, basal-like subtype 2; IM 
immunomodulatory subtype; M, mesenchymal subtype; MSL, mesenchymal stem cell-like subtype; LAR, luminal 
subtype expressing androgen receptor; UNC, unclassified. 
(http://onlinelibrary.wiley.com/doi/10.1002/cncr.28914/full#cncr28914-fig-0001). 
 
1.1.4.5 New promising targeted therapies 
In recent years new strategies have been developed. Among new agents, Cyclin-
dependent kinases 4 and 6 inhibitors are largely used, as Palbociclib, to target the 
Cyclin D-cyclin-dependent kinases 4/6-retinonoblastoma pathway that controls the 
cell cycle restriction point. mTOR pathway (mammalian target of rapamycin) is often 
activated in breast tumor and can represent a resistance mechanism to hormonal 
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therapies of which the most commonly used is Everolimus. New promising agents are 
Poly ADP-ribose polymerase (PARP) inhibitors, that block PARP enzymes activity, 
critical for appropriate recognition and repair of DNA breaks in cells with BRCA1/2 
mutations. In this way, inhibition of PARP further compromises DNA repair leading to 
cell death. PARP inhibitors seem to be an attractive therapeutic options especially for 
BRCA-mutated cancers and TNBCs (38). 
 
1.1.4.6 Androgen receptor antagonists 
Recently, it has been shown that there is a subset of ER/PgR negative tumors 
expressing genes known to be direct targets of ER and responsive to estrogens, or 
usually expressed in ER positive breast tumors which are driven to proliferate by 
androgens (39). This has led to the development of non-steroidal anti-androgen 
Bicalutamide for the treatment of patients with subtype ER/PgR negative, but AR 
positive. In a study including 436 patients only 12% were positive for the expression of 
AR, and after Bicalutamide treatment for at least 12 weeks, only 4/21 patients had 
stable disease for more than 6 months, suggesting a probable efficacy in this patient 
group (40). 
 
1.1.4.7 Metformin 
Metformin is largely used in the treatment of diabetes mellitus type 2 reducing insulin 
resistance and diabetes-related mortality. Currently, there are wide pre-clinical studies 
and data showing the possible anticancer effect of Metformin in all breast cancer 
subtypes, as well as in cytotoxic therapy-resistant models. In a population-based study 
was observed the reduction of cancer risk after administration of Metformin to 
patients with diabetes mellitus type 2 (41, 42). The effects of Metformin were also 
investigated in TNBC cell lines. Liu et al. showed the anti-TNBC effects of Metformin 
both in vitro and in vivo, demonstrating the inhibition of cell proliferation, colony 
formation and apoptosis induction (43). Again, another study reported that Metformin 
can target JAK2/Stat3 signaling inhibiting proliferation and reducing P-Stat3 and P-
mTOR levels in TNBC cell lines (44). On the basis of these and other studies, the anti-
cancer activity of Metformin was hypothesized and should be explored as a therapeutic 
agent against TN aggressive subtype. There are currently several ongoing prospective 
clinical studies investigating the safety and efficacy of this agent in cancer patients. 
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1.2 Sex Hormone Receptors in Breast Cancer 
Biological, epidemiological and clinical data strongly implicate the role of sex 
hormones, principally estrogens, in breast cancer yet their presence does not implicate 
the origin of malignant process. Despite the simple mechanism of ligand/receptor 
construct, the molecular machinery by which sex hormones regulate different 
processes in their target tissues are really more complex. The link between breast 
cancer and estrogens has always been recognized, but the real explanation for how 
these hormones exert their actions is perpetually under investigation. Protein 
receptors play a key role in hormonal actions including estrogen-stimulated growth of 
breast cancer cells. Sex hormone receptors belong to the steroid/thyroid superfamily 
of nuclear receptors and mediate the genomic action of estrogens by acting as ligand-
dependent transcription factors. All receptors share three distinct but not 
autonomously functioning domains (Fig. 5). The first domain is NH2 – terminal domain 
(NTD) that contains activating factor 1 (AF-1), the function of which is to mediate 
interaction between transcription factors and target-gene activation. The DNA-binding 
domain (DBD) contains two highly conserved zinc-finger regions necessary for high-
affinity binding to estrogen response elements (EREs) in target genes and 
comodulating receptor dimerization with the ligand-binding domain (LBD). The third 
domain is the C-terminus that mediates ligand binding, receptor dimerization and 
nuclear translocation. Finally, AF-2 domain.  
17 
 
 
Fig. 5  (a) Estrogen receptor gene and protein (b) Androgen receptor gene and protein 
 
1.2.1  Estrogen Receptor Signalling  
Estrogens play a central role in reproduction and are regarded as the powerful female 
hormones involving reproductive capacity. Nowadays, estrogen is no longer viewed 
just as a female sex hormone but rather as a steroid hormone acting in both females 
and males. In addition to their central role in reproduction, estrogens also affect the 
cardiovascular, skeletal, immune and nervous systems and play a pivotal role in the 
initiation and progression of breast cancer and osteoporosis (45). All these functions 
are achieved both through the action of the endogenous estrogens: E1 (Estrone), E2 
(Estradiol/17-beta Estradiol) and E3 (Estriol). Estrogen receptor has always been 
associated with breast cancer in two different ways: first, ER is the first element used 
for the assessment of endocrine therapy; then, it is a prognostic factor, as it is 
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associated with improved disease outcome. Molecular characterization of ER became 
possible when the ER gene was cloned by the Chambon Group (46), then, through 
mutagenesis studies, its structure was identified. Traditionally, estrogens act as 
nuclear transcription factors, interacting with coactivator or corepressor proteins, 
histone-modifying enzymes and proteins to modulate target genes through complex 
interaction. The pleiotropic and tissue-specific effects of estrogens are mediated by the 
differential expression of two distinct ER subtypes: ER-Alpha (ER-α) and and ER-Beta 
(ER-β), and their coregulators (47). The activities of a plethora of ER-interacting 
proteins converge to confer distinct functionalities on ERs, including the activation and 
repression of transcription, the integration of intracellular signaling pathways and the 
control of cell cycle progression. Both ERs are distributed widely in both genders. ER-α 
predominates in the uterus and mammary gland, whereas ER-β has significant roles in 
the central nervous, cardiovascular, and immune systems, urogenital tract, bone, 
kidney, and lungs. Typically, the majority of either ER-α or ER-β is found in the 
cytoplasm and nucleus. However, small amounts (2%) can associate with the cell 
membrane. The classical mechanism of steroid hormone action involves nuclear 
interactions of intracellular receptors, which are either cytoplasmic or nuclear. Binding 
of estrogens to ER releases the receptor from an inhibitory complex with HSPs (Heat 
Shock Proteins) and triggers conformational changes to allow ER-ligand binding to the 
palindromic ERE (Estrogen Response Element) located in the target gene promoters, 
stimulating gene transcription. Transcriptional activity requires the implication of 
AF1/AF2 domains. The transcriptional activity is also enriched by several regulatory 
cofactors including chromatin-remodeling complexes, coactivators and corepressors. 
Coactivators generally do not bind to the DNA but are recruited to the target gene 
promoters through protein-protein interactions with the ER. Some ER coactivators are 
members of the p160/SRC (Steroid Receptor Coactivator) family, as SRC1/NcoA1 
(Nuclear Receptor Coactivator-1), NcoA2, NCOA3/AIB1/TRAM1/RAC3, CBPs (CREB-
Binding Proteins) and p300 and the family of CITED (CBP/P300-Interacting 
Transactivator, With Glu/Asp-Rich Carboxy-Terminal Domain) proteins. Corepressors 
including NCoR (Nuclear Receptor Co-Repressor) and MTA1 (Metastasis Associated-1) 
protein have been implicated in the transcriptional silencing. The balance of receptors, 
coactivators and corepressors is a critical step in the classical pathway and it is crucial 
to promote signaling. A second classical mechanism of action involves protein-protein 
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interactions: in this pathway, ER-ligand complexes interact with transcription factors 
such as NF-KappaB (Nuclear Factor-KappaB), activator protein-1 and SP1 (Specific 
Protein-1) to influence gene transcription. There are different pools of ER in the 
cellular environment, including the plasma membrane, the mitochondria and the 
endoplasmic reticulum: in general, about 80% of ERs localize in the nucleus in the 
absence of estrogen, then ligand stimulation leads to nuclear accumulation and 
subsequently subcellular distribution of ER content varies from cell to cell. Over the 
years, studies have provided several critical aspects of estrogen signalling at the 
transcriptional level. In addition to traditional mechanism of action of ER, 
investigations have shown the existence of alternative rapid and nongenomic steroid 
actions. The nongenomic signalling includes the recruitment of second messengers 
such as NO (Nitric Oxide), RTKs (Receptor Tyrosine Kinases), GPCRs (G-protein–
Coupled Receptors), and protein kinases including PI3K (PhosphatidylInosiol-3-
Kinase), serine-threonine kinase Akt, MAPK (Mitogen-Activated Protein Kinase) family 
members and PKA and PKC (Protein kinases). The activation of GPR-30, a novel 
transmembrane intracellular estrogen-binding protein (48), and Akt pathway lead to 
antiapoptotic cascade. Activation of MAPK pathway drives to downstream cytoplasmic 
events or transcriptional events involving potentiation of AF1 activity: ER-ligand 
complex induces rapid phosphorylation of the adaptor proteins Src and SHC (SH2 
Containing Protein), resulting in a SHC–GRB2 (Growth Factor Receptor Binding 
Protein-2)–SOS complex formation; this leads to the subsequent activation of Ras, Raf 
and MAPKs, including ERK-1/2 (Extracellular Signal Regulated Kinases), JNK (c-Jun N-
terminal Kinase), and p38. They are then translocated to the nucleus and participate in 
gene transcription.  
 
1.2.2   Androgen Receptor 
Androgens are commonly considered as male hormones, but they have been also 
detected at physiologically relevant levels in women (49). 
These hormones play important biological roles in females. Different species of 
androgenic hormones are present in female circulation, including testosterone, DHEA 
and androstenedione (A4) produced by the ovaries and then, also with  
dehydroepiandrosterone-sulphate (DHEAS), secreted by the adrenal glands. 
Furthermore, testosterone, DHT and their metabolites are synthesised also in breast, 
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bone and brain tissues. Testosterone levels are variable during fertile period and 
gradually decline following menopause but in contrast, adrenal androgen production 
continues also after menopause (50). Testosterone has the potential to be metabolized 
within breast tissue to E2, the most potent natural ER-  ligand, or DHT, the most 
potent natural androgen receptor ligand, via the activity of aromatase and 5 -
reductase enzymes, respectively, so this can influence the proliferative capacity of 
breast epithelial cells. Several studies have tried to analyze the possible correlation 
between circulating androgens and breast cancer growth and in general, high serum 
testosterone level has been associated with an increased risk in post-menopausal 
women; however, the relationship remains unclear and it becomes necessary to 
conduct additional studies. Androgen receptor (AR) is the intracellular receptor that 
mediates the biological effects of androgens and is a member of the family of steroid 
nuclear receptors: its structure is quite similar to that of ER (Fig. 6) and there are 
similarities between the AR and ER-  signalling pathway. AR protein levels are 
elevated (59–75% AR-positive epithelial cells) in ducts and lobules of the adult 
mammary gland and remain stable across the menstrual cycle and early stages of 
pregnancy, only showing a dramatic reduction during late stages of pregnancy and 
during lactation. In contrast, ER-α levels are lower (0–12.5% ER-α-positive epithelial 
cells) and change significantly during menstrual cycle and gestational stages (51). 
Similar patterns of AR and ER-α expression are present in the breast epithelia of 
women without breast cancer. AR has been detected in up to 85% of primary breast 
cancer and up to 75% of metastatic lesions (52), but this frequency appears to be 
variable among different breast cancer subtypes. In fact, AR seems to play different 
roles at different stages in various subtypes of the disease, so AR activity is becoming 
important in the evaluation of clinical practice. Most part of studies have demonstrated 
the possible inhibitory role of AR towards breast cancer cell lines (53,54), but some 
studies have found that androgens have a pro-proliferative activity (55,56). In 
prognostic studies about ER-  positive breast cancers, higher levels of AR confer a 
survival advantage, suggesting a possible role of AR as a tumor-suppressor in 
malignant breast epithelial cells: a probable explanation is that AR levels increase with 
the progression of ER-  positive malignancy in a homeostatic way to restore the 
balance of hormones activity normally involved in mammary epithelial cell 
proliferation. Furthermore, in ER-  positive breast cancer, AR has been found to 
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correlate with lower grade, reduced lymph node involvement and higher disease-free 
survival, proportionally to AR expression levels (57,58). In TNBCs, AR is expressed in 
10-43% but its prognostic value in this subtype remains unclear, with some studies 
suggesting an increased associated mortality (59), some indicating no influence of AR 
expression (60). Anyway, McGhan el. found that AR expression correlates with higher 
tumor stage and an increase in lymph node metastasis (61). Hu et al. analyzed 211 
TNBC cases and found that patients expressing AR had 83% of increase in overall 
mortality compared to AR-negative patients (59). Discrepancies in studies could be due 
to multiple factors, including the use of tissue microarrays vs whole-tissue sections, of 
different AR protein detection techniques, of several antibodies for AR 
immunodetection, measurement of AR mRNA trough different platform in 
trascriptome profiling studies and variable cut-off scores defining AR positivity. 
Furthermore, larger cohort numbers are necessary to determine a role for AR in 
specific patients tissues. TNBC expressing AR is called “molecular apocrine” , and it has 
been identified by Farmer et al. (62). This subtype has been studied in vitro using 
different breast cancer cell lines whose growth, demonstrated by AR silencing or 
treatment with Bicalutamide, is promoted by AR expression. Furthermore, Robinson et 
al. were able to show that, in the absence of ER- , more than a half of AR binding 
events in the genome map in a similar pattern to that of ER-  in ER-positive cells, 
promoting the expression of ER-  target genes. In this subtype AR can, in some ways, 
mimick ER-  in a transcriptionally active manner through the pioneer factor FoxA1 
and can stimulate an expression pattern more similar to that of ER-  in a ER-  positive 
cancer cell line than the profile reported for the AR in a prostate cancer cell line (63). 
Moreover, recent data show that over 90% of metastasis from luminal tumors retain 
FoxA1 expression (64) and the presence of AR and FoxA1 in metastatic lesions may 
mark a luminal to molecular apocrine transition and need an antiandrogenic rather 
than an antiestrogenic strategy. All these aspects suggest that in ER-  carcinomas AR 
can drive tumor progression and can represent a therapeutic target for this subtype of 
breast cancer. 
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. 
Fig. 6 Proposed dual role of AR in breast cancer (Hickey et al., Androgen Receptor in Breast Cancer, Mol Endocrinol. Aug 
2012) 
 
Fig. 7 Overview of pathways regulated by AR in breast cancer cells. (A) AR and ERα, (B) AR, FOXA1 and HER2, (C) AR, PTEN 
and p53 and (D) AR and cell cycle regulators (McNamara K M et al. Endocr Relat Cancer 2014;21:T161-T181) 
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1.3 Epigenetics and Cancer 
Epigenetics is a term used to describe all heritable modifications in gene expression 
that are not caused by alterations in the DNA sequence. DNA methylation and histone 
modifications are the major epigenetic mechanisms, but there are also stable and long-
term changes in the transcriptional machinery of a cell which are not necessary 
heritable. Epigenetic machinery drives critical processes such as X-chromosome 
inactivation, genomic imprinting, genomes reprogramming during differentiation and 
development, RNA interference connected to post-transcriptional gene silencing and 
genome imprinting. Deficiencies in this epigenetic mechanisms were found to be 
correlated to many human diseases including breast cancer. 
 
1.3.1 DNA methylation 
DNA methylation is the covalent post-replicative addition of a methyl group (-CH3) 
onto the 5-carbon of the cytosine ring within CpG dinucleotides,catalyzed by DNA 
methyltransferases (DNMTs), which transfer the CH3 –group from the methyl group 
donor S-adenosyl methionine. Usually gene promoters are rich in CpG dinucleotides, 
which are grouped to form a cluster called CpG islands. It is estimated that 60% of 
protein-coding mammalian genes hold CpG islands in the promoter region. In normal 
cells, CpG islands are usually unmethylated, while other single CpG dinucleotides 
throughout the genome are generally methylated. In cancer cells, on the contrary, CpG 
islands preceding tumor suppressor gene promoters are frequently hypermethylated, 
while promoter regions of oncogenes show a lower CpG methylation. 
Hypermethylation of gene promoters can lead to cell cycle regulating genes silencing, 
resulting in uncontrolled cell growth and tumorigenesis. Common genes found to be 
transcriptionally silenced via promoter hypermethylation include the cell cycle 
inhibitor Cyclin-dependent kinase inhibitor p16, the tumor suppressor gene p53, the 
DNA repair genes MLH1, MGMT and BRCA1 and the cell cycle regulator APC (65). Loss 
of imprinting and reactivation of transposable elements are the main mechanisms 
responsible of  hypomethylation of CpG dinucleotides, and this can lead to 
chromosome instability as well (66). 
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1.3.2  DNA Methyltransferases 
DNMTs hold in the C-terminal a catalytic domain that transfers methyl groups onto 
cytosine residues within DNA and they are the principal enzymes involved in 
hypermethylation of tumor suppressor genes. In mammals the DNMT protein family 
includes five members: Dnmt1, Dnmt2, Dnmt3a, Dnmt3b and Dnmt3b, but only three 
among them has catalytic methyltransferase activity (Dnmt1, Dnmt3a and Dnmt3b). 
Dnmt1 is classified as a maintenance methyltransferase because it shows a strong 
preference for hemimethylated over unmethylated DNA and its particular targeting of 
replication foci seems to allow copying of the parental DNA methylation pattern onto 
the newly synthetized DNA daughter strand (67). The Dnmt3 family has two catalytic 
members, Dnmt3a and Dnmt3b, which have methyltransferase activity towards 
unmethylated over hemi-methylated DNA, thus they are called de novo 
methyltransferases. Between the two remaining members of DNMT family, Dnmt2 and 
Dnmt3L, only Dnmt3L has shown to be able to stimulate de novo DNA methylation 
through the mediation of Dnmt3a (68). 
 
                                     Fig. 8 Representation of the 3 main DNMT transferases 
 
 
1.3.3   Histones modifications 
Histone modifications are another fundamental process involved in epigenetic gene 
regulation. Histones are the major proteins that form chromatin, which can be 
classified into two forms: euchromatin, the accessible, less-dense and early-replicating, 
and heterochromatin the inaccessible, late replicating and gene-dense. Histones are 
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globular proteins carrying N-terminal tails that can undergo several chemical reactions 
by histone deacetylases enzymes (HDACs), histone acetyltransferases (HATs) and 
histone methyltransferases (HMTs), that cause the modification of eu- or 
heterocromatin. Histone changes can silence tumor suppressor genes despite the 
lower methylation of the gene’s CpG island (an event that usually activates genes) (69). 
Gene transcription can be affected by acetylation, that modifies chromatin’s structure 
that modulates the accessibility of transcription factors to their target DNA. So, it plays 
an important role in regulation of gene expression and in tumorigenesis.  
 
1.4  microRNAs 
MicroRNAs (miRNAs) are small non-coding RNAs of about 18-24 nucleotides (nt) of 
lenght, whose role in human carcinogenesis has been identified relatively recently. For 
many decades miRNAs have remained unknown to researchers until, in 1993, Victor 
Ambros discovered them in the nematode C. Elegans. In fact, during mutation sudies 
that determined changes in the timing of the development of the nematode, Ambros 
identified through genetic screening the gene lin-4 encoding two small RNAs: one of 
about 22 nucleotides and the other of 61 nucleotides. It was observed that the shorter 
of them, interacting with the 3'untranslated region (3'UTR) of mRNA of lin-14, 
repressed its expression, thus reducing the amount of protein produced without 
changing the levels mRNA (70). The 22 nucleotide Lin-4 RNA was, by that time, 
recognized as an archetype of a large class of regulatory RNAs called "microRNAs" or 
"miRNAs". Subsequently, Reinhart et al. identified another gene coding for a second 22 
nucleotides miRNA, let-7, involved in the transition from larval to adult in C. elegans 
(71). A year later over 100 miRNAs in both D. melanogaster and humans were 
identified (72, 73).  
 
1.4.1  Nomenclature 
Names are assigned to miRNAs, before the publication of their discovery, after they 
have been experimentally confirmed. The prefix "mir" is followed by a hyphen and a 
number that often indicates the order of identification (for example miR-123 was 
discovered and named before miR-456). The letter "r" of "mir" is written in lowercase 
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or uppercase, depending on whether we refer to the pre-miRNA or mature form, 
respectively. miRNAs that have nearly identical sequences except for one or two 
nucleotides, are annotated with the addition of a lower case letter after the number 
(e.g. miR-29a, miR-29b and miR-29c). Pre-miRNAs which are located in different 
regions in the genome but that generate a mature form identical to 100%, are indicated 
with an additional suffix in figures (e.g. the pre-miRNA hsa-mir-194-1 and hsa-miR-
194-2 are located in different regions of the genome, but generate an identical mature 
miRNA: hsa-miR-194). In addition, a three-letter prefix identifies the species of origin 
(e.g. "hsa" for Homo sapiens, "mmu" for Mus musculus, "gga" for Gallus gallus and "rn" 
for Rattus norvegicus). Other prefixes that are used include "v" for a miRNA encoded 
by a viral genome, and "d" for a miRNA belonging to D. melanogaster. When two 
mature miRNAs are derived from opposite strands of the same pre-miR, these are 
marked with the suffix "-3p" or "-5p", which indicate respectively the filament "sense" 
and "antisense", previously indicated by the suffixes "s" and "as". Finally a miRNA is 
distinguished by its level of relative expression, if known, with an asterisk following 
the name: this indicates the miRNA resulting from double hairpin structure that is at 
higher levels in the cell (74).  
 
1.4.2  Biogenesis and degradation 
Approximately 50% of miRNAs is embedded in introns of protein coding genes, or in 
non-coding RNA transcripts, thus identifying two different classes of transcription of 
miRNAs, "exonic" and "intronic", which require however similar biogenesis 
mechanisms. The transcription of a large number of miRNAs is then associated with 
the expression of host gene promoters, while other miRNAs are grouped into 
polycistronic transcripts, thereby allowing a coordinated expression (75). The miRNA 
is first transcribed in the nucleus by RNA polymerase II/III in a long precursor with a 5' 
CAP and a poly-A tail at the 3' (pri-miRNA) (76). The pri-miRNA is then transformed 
into an RNA of 70-100 nucleotides, with a hairpin structure (pre-miRNA), by a RNA-
specific ribonuclease called Drosha, with the help of Dgcr8 (DiGeorge syndrome critical 
region gene 8, or Pasha) (77). Through Exportin 5 pre-miRNA is translocated into the 
cytoplasm, where a complex including Dicer (ribonuclease III) and TRBP (HIV-1 
transactivating response RNA binding protein) cuts it in a duplex of 18-24 nucleotides, 
that interacts with an another large protein complex called RISC (RNA induced 
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silencing complex), comprising the Argonaute family proteins (Ago1-4 in humans). 
Once it is inside the complex, the two strands of the duplex miRNA: miRNA * are 
separated and followed by two different ways. The 3'-5’ strand (miRNA *) is released 
into the cytoplasm where it is degraded, and the 5'-3'strand (mature miRNA) remains 
stably associated with RISC that mainly drives it, but not exclusively, to the 3' 
untranslated region (3'-UTR) of the target mRNA. It was recently shown that targeting 
can also occur in the 5' untranslated region (5'-UTR) and in the open reading frame 
(ORF) (78). Anyway, the decay process of miRNAs is still little known topic. Although 
initially miRNAs were considered very stable molecules, with a half-life of the order of 
days, recently "microRNases" involved in their turnover have been identified, as SDN in 
plants (small RNA degrading nucleases) and XRN-2 in animal cells (exoribonuclease 2). 
It seems that miRNAs, once completed their activity, or not having another target 
messenger, disassociate themselves from RISC complex and are led to degradation. It is 
emerging that a half-life of long duration is not considered as an invariant 
characteristic of miRNAs, but there are marked differences in their individual stability, 
furthermore the environment of the cell can influence the rate of turnover. Biochemical 
data support the hypothesis that the target mRNA can stabilize the complex miRNA-
Ago, providing a possible mechanism that could control the duration of miRNA-life. 
Anyway, miRNAs turnover mechanisms are still largely unknown (79). 
 
1.4.3  miRNAs function 
miRNAs exert their regulation gene expression function through the control of the 
translation and the expression of their target mRNAs, and they are involved in a variety 
of biological processes (80,81). Following the association between miRNA-RISC 
complex and the target mRNA, the latter can undergo two different ways based on the 
complementarity degree of miRNA:mRNA. A perfect complementarity between base 
pairs leads to cleavage of the target (this occurs primarily in plants), while in the case 
of an imperfect annealing, silencing of the target mRNA will take place (predominant 
mechanism in nematodes and mammals), although in the latter case also a reduction of 
the target mRNA has been described (82). Recently, it was discovered that some 
microRNAs are able to up-regulate the translation of their specific targets. In fact, 
during cell cycle arrest, it seems that microRNAs, with the help of proteins such as AGO 
and FXR1, can activate the expression of a target gene recognizing target sites enriched 
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in AU elements (ARES) in the 3 '-UTR sequence (83). MiRNAs have their specificity and 
if we consider a number of different organisms, it is clear that miRNAs are 
differentially expressed during development stages, in different cell types and in 
various tissues (84). It has been estimated that approximately 9% of all mammal genes 
presents, in the 3'-UTR region, more than one target site for miRNAs and that 1314 of 
these genes are considered to be good candidates as target of miRNAs regulation, 
carrying more than two recognition sites. Despite this, it is not a rule that all predicted 
miRNA-mRNA pairs produce a biological effect, unless both RNAs are not expressed 
simultaneously in the same cell and in a sufficient concentration (85). Since only 
nucleotides from 2 to 8 of the 5'-UTR pair up perfectly with the 3'-UTR region of the 
mRNA target, identification of target mRNAs is quite complex (82, 86). Nucleotides not 
involved can pair with the sequence of the mRNA, but in most cases this is not 
necessary for the purposes of the intrinsic functionality of the molecule. Some miRNAs 
can indeed act as small interfering RNAs (siRNAs) by inducing cleavage of mRNA by 
forming a duplex miRNA: mRNA made possible by pairing between nucleotides in 
position 10 and 11, or it can happen that the extension of bases pairing between 
miRNA and mRNA can induce a balance between cleavage and degradation of the 
target (87). Studies carried out using bioinformatic algorithms applied to the 
probability of pairing between the first 2-8 bases of the sequence of mature miRNAs 
and the 3'-UTR of all human genes expressed, have highlighted that miRNAs are able to 
bind to more than a hundred target genes with different functions and that a single 
target gene can be regulated by different miRNAs (88,89). There are many algorithms 
developed in order to identify possible and probable target genes of a miRNA and, vice 
versa, miRNAs targeting a single gene. Among the most commonly used are cited 
DIANA-microT, TargetScan, Miranda and PicTar (85, 90, 91). Several papers, however, 
reported error rates associated with the analysis of these algorithms that suggest 
researchers to use more than one of these systems. In fact, as reported by Wei Wu et al. 
who examined all results obtained with these algorithms about a miRNA, more than 
81% of miRNA:mRNA pairings are predicted by a single algorithm examined, while the 
false positive rate for each algorithm is around 20-30% (88). Literature also suggests 
to validate the predicted target, for example using luciferase assay (92). The exact 
mechanism of action of miRNAs is not yet completely undestood. Some studies suggest 
a repression of translation by association of the miRNA with the mRNA-ribosome 
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complex, before the process begins. Other studies support the hypothesis that this 
inhibitory action takes place once translation is started, following three possible 
modalities: impediment of elongation of the polypeptide due to a stacking of ribosomes 
along mRNA strand, direct action of the miRNA on the ribosome with induction of 
cleavage of two ribosomal subunits, instant degradation of the polypeptide during the 
elongation due to a protease activated by miRNA (93). MiRNAs can than participate 
actively in all molecular processes regulating them. 
 
 
 
Fig. 9  Biogenesis of miRNAs and strategies employed to modulate miRNA activity: miRNA mimics and miRNA 
inhibitors 
 
1.4.4  microRNAs and cancer 
More than 50% of genes encoding miRNAs was found to be located in genomic regions 
associated with cancer (CARGs), about 19% within or adjacent to fragile sites of the 
genome (FRAs) and 43% was found in amplified genomic regions, or with frequent loss 
of heterozygosity (LOH) (94). It is therefore easy to understand the wide involvement 
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of miRNAs in carcinogenesis. Some miRNAs may have a dual function in cancer cells. 
Onco miRNAs and miRNA tumor suppressors may represent two different sides of the 
same gene, which can act in one way or another depending on tissue types and specific 
targets (95). Therefore, knowledge of expression profiles of miRNAs in various tumors 
could potentially have a significant diagnostic value, while the role of miRNAs as 
biomarkers for the prognosis of patients now seems to be evident (96). The study of 
these molecules has become of great interest to investigate rare and aggressive tumors, 
being very complicated to manage from the therapeutic point of view. The important 
role played by these small RNAs is confirmed by the evidence that they are often 
deregulated in tumor tissues (97). MiRNAs are frequently dysregulated in cancer 
patients. The group of Volinia has performed a detailed analysis of a large-scale 
expression profiling of miRNAs in 540 samples of 6 solid tumors (breast, colon, lung, 
pancreas, prostate and stomach). 137 different miRNAs, expressed in at least 90% of 
the samples analyzed, were considered. By comparison of all tumor tissues with all 
healthy tissues a change in expression of 31% of the total analyzed miRNAs has been 
revealed: 26 miRNAs were overexpressed and 17 under-expressed. In order to identify 
prognostic miRNAs, Volinia et al. have found a tissue-specific signature that can 
unequivocally be attributed to a particular tumor subtype.  Among overexpressed 
miRNAs in all neoplasias. They found miR-21, miR-17-5p and miR-191, and in the same 
way 21 deregulated miRNAs have been identified, in at least three of the six solid 
tumors analyzed. Results have shown that prostate, colon, pancreas and stomach 
tumors have a very similar pattern, while lung and breast cancers show a quite 
different profile. A group of miRNAs that appears to be activated includes miR-210 and 
miR-213 that, with miR-155, represent the only overexpressed miRNAs in both breast 
and lung carcinomas, suggesting that in solid tumors the change in miRNAs expression 
seems to be unique, regardless of tissue’s origin, and a common mechanism of 
involvement in carcinogenesis. In solid tumors, an increase of expression seems the 
most common event, while the loss of expression appears to be less frequent and more 
related to tissue specificity (98). 
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1.4.5  miRNAs in breast cancer 
MiRNAs have been shown to play a critical role in the regulation of a wide range of 
pathological processes, including breast cancer. The first study describing genome 
profiling of miRNA in breast cancer identified 29 differentially expressed candidates, 
and 15 of them were used to distinguish between breast cancer and normal breast 
tissue (99). Furthermore, a correlation between some miRNAs and clinicopathological 
features, such as ER, PgR and Her2/neu status, tumor size or lymph node status, was 
found. In particular, the expression loss of members of the let-7 family was associated 
with clinical features, such as PgR status (let-7C), a positive lymph node status (let-7f-
1, let-7a-3 and let-7a-2) or an high proliferation index (let-7c and let-7d) (100). Some 
miRNAs are classified as oncogenic because of their capacity to repress tumor 
suppressor genes, and numerous miRNAs have been demonstrated to be implicated in 
oncogenesis and/or metastasis process, that promote angiogenesis or induce 
epigenetic changes. For exemple, miR-10b is shown to be upregulated in breast cancer 
cells and correlated with increased cell migration and metastasis (101). Several studies 
have suggested that miR-155 is an oncogenic miR and its upregulation results in 
inhibition of tumor suppressor genes in breast cancer cells (102,103). Similarly, miR-
21 upregulation was demonstrated in breast cancer cells and is considered as an 
oncogenic miRNA (104). Recently, miR-203 also has been shown to inhibit tumor 
suppressor protein SOCS3 expression in breast cancer cells (105). Other central miRs 
are represented by the miR-200 family which shows a role in cell stemness, cell 
proliferation, apoptosis also in vivo and it is implicated in the promotion of metastasis 
in breast cancer, reason why they are referred as MetastamiRs (106,107). Other central 
metastamirs include miR-520C, miR-373, miR-221, miR-222 and miR-9 (108). 
Furthermore, Zhao et al. reported that miR-221 and miR-222 overexpression 
contributes to tamoxifen resistance through negative regulation of ER-α, whereas 
knockdown of miR-221 and/or miR-222 restores ER-α expression and tamoxifen 
sensitivity (109), so they are part of that class of miRNAs implicated in drug resistance 
to chematerapeutic agents. Recently, miR-451 and miR-27 were shown to be involved 
in resistance of MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin 
mediated by MDR-1 (110), and miR-328 was shown to regulate negatively the 
expression of the ATP binding cassette membrane transporter BCRP (111). 
Additionally, Kong et al. demonstrated that miR-155 contributes to chemoresistance in 
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breast cancer (112). Over the past decade, certain miRNAs have been reported as 
circulating in serum/plasma from cancer patients (113) and since then, several very 
interesting studies have revealed associations between circulating miRNAs and the 
presence of cancers, including breast cancer (114). Cuk et al.  were able to associate for 
the first time circulating miR-127-3p, miR-376A and miR-652 to breast cancer, 
together with miR-148B, miR-376C, miR-409-3p and miR-801, finding them at 
significantly higher levels in the plasma of breast cancer patients when compared to 
healthy women (115), underling their potentially noninvasive biomarkers role. More 
recently, the group of Fabbri et al. has shown that exosomes released by lung cancer 
cells contain specific miRNAs, such as miR-21 and miR-29A, are able to bind and 
activate Toll-like receptors (TLR8 in humans and TLR7 in mice) in immune system 
cells surrounding the tumor tissue, and that are located in the interface between tumor 
tissue and healthy tissue. The activation of TLR by these exosomial miRNAs, triggers 
the pathway of NF- B which leads to an increase in the production of interleukin-6 (IL-
6) and tumor necrosis factor-alpha (TNF-α) by immune system cells, resulting in tumor 
growth and metastatic potential. This discovery has revealed a mechanism of action of 
miRNAs completely new, and the importance of exosomes as mediators of the cross-
talk between tumor cells and the tumor microenvironment surrounding deserves to be 
mentioned (116). Furthermore, miRNAs have been shown to be able to trigger a 
prometastatic inflammatory response TLR-mediated (117). In breast cancer as well, 
some studies have been performed. For example, Melo et al. have found that exosomes 
derived from metastatic breast cancer cells showed higher enrichment in certain 
miRNAs when compared to exosomes derived from non metastatic breast cancer cells 
(118). Further investigation is certainly warranted to increase the understanding of 
circulating miRNAs as potential diagnostic, prognostic, and predictive biomarkers.  
On the other side, some miRNAs are associated with tumor suppressive activity in 
breast cancer. So far, the most widely studied were miR-125A and miR-125B, 
associated with a reduction of the stress-induced RNA-binding protein HuR and 
therefore with a reduction in cell proliferation and migration and with increased 
apoptosis (119). Also miR-27B, miR-17-5p, miR-205, miR-206 and miR-145 are 
commonly considered tumor suppressive miRNAs in breast cancer, due to some 
evidences suggesting their role in the reduction of cell proliferation (120, 121, 122). 
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Fig. 10 Some major deregulated miRNAs in breast cancer  
 
1.4.6 The miR-29 family and DNMTs 
The family of miRs-29 (miR-29A, -29C and -29C) is downregulated in NSCLC (Non-
small-cell lung carcinoma), as demonstrated by Fabbri et al. In in vitro experiments, the 
Authors have shown that miR-29s are able to target genes encoding DNMT3A and 
DNMT3B. They evaluate protein expression in 172 samples of healthy and tumor lung, 
and found a significant correlation between high expression of Dnmt3A and shorter 
survival, while this has not been observed with Dnmt3B. Expression level of mRNA has 
appeared inversely correlated with levels of miR-29s in NSCLC tissues. In addition, the 
analysis was extended to expression levels of mRNAs of two tumor suppressor genes, 
FHIT and WWOX, which are frequently silenced by methylation in promoter region. 
Transfection of miRNA-29A, -29B and -29C in lung adenocarcinoma cell lines led to a 
reduction of the expression of DNMT3A and 3B and induced demethylation of the 
promoter of FHIT and WWOX, resulting in their re-expression and inhibition of 
tumorigenicity in vitro and in vivo. This study confirms an important role of miRNAs as 
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regulators of epigenetic mechanisms involved in carcinogenesis (123). Also miR-148A 
and -148B have found to be involved in regulation of the coding sequence of Dnmt3B 
(124). 
 
1.4.7 miRNAs and AR 
Several studies have proposed a correlation between specific microRNAs and the 
expression of androgen receptor. Particularly, some androgenic-inducible microRNAs 
(miR-21, -101, -125b, -221, and -222) have been well-characterized in prostate cancer 
cells and found to be involved in the process of tumor progression associated with 
androgen (125). For instance, the onco-miR-21 has an androgen responsive element 
(ARE) within its promoter region and is directly up-regulated by androgens in prostate 
cancer cell lines. Again, 13 miRNAs (miR-135B, miR-185, miR-297, miR-299-3p, miR-
34A, miR-34C, miR-371–3p, miR-421, miR-449A, miR-449B, miR-634, miR-654–5p, 
and miR-9) has been validated, able to regulate the 3’-UTR of AR and it has been 
demonstrated that some of them decreased androgen-induced proliferation of prostate 
cancer cells (126). Then other studies have been performed to investigate the role of 
microRNAs in AR pathway and, in breast cancer, the first evidence that highlights 
androgen-inducible miRs is reported to be miR-363 (127). 
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2. Aim of the thesis 
 
Breast cancer is still a highly heterogeneous disease, characterized by differences both 
in biological features and in the response to the various existing therapies. Molecular 
biology and the latest discoveries in genetics have had a big impact on different aspects 
of prevention, prognosis and response to treatment. However, although in recent 
decades there have been improvements about hormone therapy, effective treatment 
options remain still limited mostly against TNBCs. In particular, the lack of expression 
of ESR1 in TNBCs is due in most cases to promoter hypermethylation. Promoter 
hypermethylation of tumor suppressor genes is one of the best known mechanisms 
involved in carcinogenesis. Consequently, the study of methylation has recently 
become a central theme in oncology research. Tumorigenesis is in fact a process 
characterized by an altered methylation status of key genes (tumor suppressor genes / 
oncogenes), as a result of increased expression of DNA methyltransferases (DNMTs). 
The genomic hypomethylation can lead to chromosomal instability and an increased 
mutation rate, thereby accelerating the progression of carcinogenesis. It was found 
that DNMT3B was overexpressed in 30% of breast cancers, and this appeared 
significantly related to the histological grade III, the negativity of ER and a marked 
expression of MK167 (128), suggesting that DNMT3B could represent a marker of 
aggressiveness and cancer proliferation, being the overexpression a cause of tumor 
growth rather than a consequence of it. Epigenetic factors and microRNAs are often, in 
cancer, deregulated in their activities. A close association between miRNAs and 
epigenetics is so established, as the same epigenetic mechanisms can sometimes be 
responsible for aberrations in the miRNoma (defined as the full spectrum of miRNAs of 
a specific genome). In fact, miRNAs are subject to the same rules of epigenetic 
regulation of any other coding gene and a specific group of miRNAs, called epi-miRNAs, 
can affect directly the effectors of epigenetic mechanism, such as DNMTs or HDACs 
(129). Furthermore, also ER has been demonstrated to be regulated by microRNAs, 
such as miR-206 that silences ER in in vitro studies (130). On the basis of these 
evidences and referring also to the study of Fabbri et al. (123), we have hypothesized 
that treatment with epi-miRNAs could lead to restoration of normal methylation 
pattern of ESR1 and then to its re-expression in TNBCs, finally re-establishing the 
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sensitivity to SERMs, particularly to Tamoxifen. Subsequently, being reported that 10-
43% of TNBCs are positive for the expression of the androgen receptor (AR) (61) and 
that it is expressed up to 90% in primary tumors (52) and in 25% of metastases (40), 
we have speculated a possible involvement in the proliferation of TNBCs. There are 
experimental evidences which support this hypothesis, showing that AR represents a 
potential oncogene, especially in molecular apocrine subtype, in which AR seems to 
assume the role of the Er-α, where the latter is not expressed (63). So, we tested in 
vitro the modulation of AR operated by miRs, and in the same time we  evaluated the 
effect of 3 drugs (Tamoxifen, Herceptin and Metformin), in order to consider a possible 
increase to their sensitivity, after AR silencing. 
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3. Materials and methods 
 
3.1 Cell cultures 
The human breast carcinoma cell line MDA-MB 231 and MDA-MB 453 were purchased 
from ATCC (American Type Culture Collection), and the cell line T-47D was gently 
purchased from Biochemistry, Biophysics and General Pathology Department of 
University of Naples. MDA-MB 231 and MDA-MB 453 were maintained in Leibovitz’s L-
15 medium (ATCC 30-2008, LGC Standards) supplemented with FBS (Foetal Bovine 
Serum) to a final concentration of 10%, according to the information sheet of the 
manufacturer. T-47D were maintained in RPMI-1640 medium (ATCC 30-2001, LGC 
Standards) supplemented with 10% FBS and 0,1 % Insulin Solution (Sigma-Aldrich). 
Penicillin-streptomycin (PAA, Carlo Erba Reagents) to a final concentration of 1% and 
MycoZap Prophylactic (Lonza) to a final concentration of 0,002% were added to all 
mediums. The cultures were maintained in an incubator Heraeus, in atmosphere 
composed of 95% air and 5% CO2. Every four days we proceeded to sub-cultivation of 
cell lines by using Trypsin-EDTA (PAA, Carlo Erba Reagents). Cell lines were tested 
every two months with MycoAlert ™ Mycoplasma Detection Kit (Lonza LT07-418, 
Euroclone) to check a possible contamination by mycoplasma. 
 
3.2 Pre-miRNAs Transfection 
Pre-miRNAs (pre-miRNA miR precursors, Ambion) and the corresponding negative 
control, SCR (Pre-miR miRNA precursor scrambled negative control # 1, Ambion) were 
used to transfect breast cancer cell lines, at a final concentration of 100 nM , with 
Lipofectamine 2000 (Invitrogen), in accordance with the instructions provided by the 
manufacturer. RNA and proteins were extracted from cell pellets collected at 24-48-
72h after transfection, depending on the type of analysis.  
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3.3 Extraction of RNA and proteins 
RNA was isolated with mirVana ™ miRNA Isolation Kit (Ambion, Invitrogen), following 
the protocol provided by the manufacturer. The quantification of extracted RNA was 
carried out using NanoDrop ND-1000 (Thermo Fisher Scientific). Total proteins were 
extracted, keeping samples on ice, with 1X RIPA lysis buffer (Santa Cruz Biotechnology) 
with the addition of 10 µl of PMSF, 10 µl of sodium orthovanadate and 15 µl of protease 
inhibitors, per ml of 1X RIPA lysis buffer, as recommended by the datasheet attached to 
the product. Then proteins were quantified following the protocol of the BCA Protein 
Assay (Pierce, ThermoScientific) and using a Multiscan EX microplate reader (Thermo 
Labsystems), with a wavelength filter of 490nm. 
 
3.4 Protein expression analysis 
Western blotting was used as a method of analysis to evaluate the expression of ER-α 
and AR. Proteins (20-50 µg) were denatured and separated by electrophoresis using a 
gel Criterion TGX Stain Free Gel Precast 4-20% (Bio-Rad Laboratories) and Laemmli 
Sample Buffer (Bio-Rad) with 5% of β-mercaptoethanol (Carlo Erba Reagents), in 1: 1 
ratio with the sample. Electrophoretic run was performed at a constant voltage of 200V 
in a TRIS/Glycine/SDS 1X buffer (Bio-Rad). Proteins were then transferred on a PVDF 
membrane (Trans-Blot Transfer Turbo midi-format 0.2µm; Bio-Rad Laboratories) 
using the Trans Blot Turbo System (Bio-Rad Laboratories). The membrane was 
subsequently incubated for 2 hours at room temperature in a solution of Tween 20 
(Bio-Rad) at 0.1% and 1X Dulbecco's Phosphate Buffered Saline (PBS; Invitrogen) 
supplemented with 5% milk powder (Blotting Grade Blocker Non Fat Dry Milk; Bio-
Rad) in order to facilitate the saturation of non-specific binding sites. Primary 
antibodies and dilutions used are the following:  
 Estrogen Receptor α (D6R2W Cell Signaling) 1:1000 
 Androgen Receptor Antibody (#EPR1535(2) Abcam) 1:1000 
 Vinculin clone FB11 (IgG1) monoclonal Ab (Biohit) 1:1000 
 Beta Actin [AC-15] Antibody (HRP) (ab49900 Abcam) 1:50.000 
Secondary antibodies and dilutions used are the following: 
 Goat anti-rabbit IgG-HRP (Santa Cruz) 1:2000; 
 Goat anti-mouse IgG-HRP (Santa Cruz) 1:2000; 
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 Precision Plus Protein Western C StrepTactin-HRP Conjugate (Bio-Rad) 
1:10000; 
 Biotinylated Protein Ladder (Cell Signaling) 1:1000 
 
Blocking and immunological reactions were performed in accordance with the protocol 
Western Immunoblotting of Cell Signaling. The antigen-antibody reaction of 
chemiluminescence was performed using the SuperSignal West Femto (Pierce Thermo 
Scientific), the image was acquired using the Chemidoc (Bio-Rad) and analyzed using 
ImageJ Software. 
 
3.5 miRNAs and mRNAs expression analysis 
The analysis of the expression of miRs, for the evaluation of the efficiency of 
transfection, was performed using the TaqMan miRNA Assays (Applied Biosystems, 
Lifetechnologies). Briefly, the molecule of complementary DNA (cDNA) was synthesized 
using 10 ng of RNA as template, a Reverse Transcription gene-specific primer and 
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Lifetechnologies). 
The expression of DNMT1, DNMT3A, DNMT3B and ESR1 was evaluated with the use of 
the TaqMan Gene Expression Assays (Applied Biosystems, Lifetechnologies). The cDNA 
was synthesized using 80ng of RNA as a template and the TaqMan RT PCR Kit (Applied 
Biosystems, Lifetechnologies). Quantitaive Real-Time (qRT-PCR) was performed with 
Applied Biosystems 7500 Real-Time PCR System (Lifetechnologies) using cDNA, 
TaqMan probes and TaqMan Universal PCR Master Mix (Applied Biosystems, 
Lifetechnologies). Experiments were conducted in triplicate and normalized to RNAU44 
or GAPDH, used as internal controls (housekeeping genes). Relative expression levels 
were calculated using the method of comparative Ct (ΔΔCt method). 
 
3.6 siRNA transfection 
SMARTpool siGENOME AR siRNA (Dharmacon) and the corresponding negative 
control, siGENOME Non-Targeting siRNA #1 (Dharmacon), were used to perform AR 
silencing transfection, at a final concentration of 50 nM , with Lipofectamine RNAiMAX 
(Invitrogen), in accordance with the instructions provided by the manufacturer. RNA 
and proteins were extracted from cell pellets collected at 24-48-72-120-144h after 
transfection, depending on the type of analysis.  
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3.7 Drugs preparation 
Tamoxifen ((Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene, trans-2-[4-
(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine) was purchased from 
Sigma-Aldrich in powder formulation and a working solution was prepared in Dimethyl 
sulfoxide (DMSO) (CrioServ Bionichepharma) to obtain a 100 mM concentration; 
tamoxifen was then tested at 0,5-1-5-10 μM and DMSO never exceeded 0,1%. 
Metformin (1,1-Dimethylbiguanide hydrochloride) was purchased from Sigma-Aldrich 
in powder formulation and a 100 mM working solution was prepared in fresh medium; 
metformin was then tested at concentrations of 5-10-20-40 mM. Herceptin was 
provided by the Pharmacy of our Institute at a concentration of 20 mg/ml, dissolved in 
sterile water and and 1 mM solution was used to perform experiments. After 24h post 
silencer-transfection, cells were trypsinized and seeded in 96-well plates. The day after 
cells were exposed to treatments at the different concentrations described above. The 
effect of Tamoxifen and Metformin was investigated at 24-48 and 72h, while that of 
Herceptin at 120-144 h.  
 
3.8 CellTiter-Glo® Luminescent Cell Viability Assay 
The CellTiter-Glo® Luminescent Cell Viability Assay (Promega) is a homogeneous 
method used to determine the number of viable cells in a culture, and it is based on the 
quantification of present ATP that indicates the existence of metabolically active cells. 
The procedure, according to the instructions provided by the datasheet, involves the 
adding of a single reagent (CellTiter-Glo ® Reagent) directly to cultured cells. This 
system "add-mix-measure" produces a cell lysis and the generation of a luminescent 
signal proportional to the ATP content, which, in turn, is directly proportional to the 
number of cells that are in culture. 
 
3.9 Bromodeoxyuridine assay 
After cells were seeded in 6-well plates and treated with Herceptin, they were 
incubated with a 60 μM Bromodeoxyuridine (BrdU) solution in 1 ml of medium. Cells 
were then centrifuged and fixed with 70 % of cold ethanol. The day after cells were 
washed in PBS 1X and incubated with first HCL 2M, then sodium tetraborate and 
Tween 20 0.5% + BSA 1%. Finally cells were incubated for 1 hour first with anti-BrdU 
antibody following a 1:50 diluition, secondly with a FITC-conjugated secondary 
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antibody diluted 1: 250 for 1 hour. After antibodies incubation, cells were washed with 
PBS 1X, stained with propidium iodide solution and incubated overnight at 4°C. The 
day after samples were analyzed by flow cytometry.  
 
3.1 Data analysis 
Data obtained from qRT-PCR were analyzed by Life TechnologiesTM 7500 Software 
v2.0.6 for 7500 Fast Real Time PCR System. Relative expression levels were calculated 
using the method of comparative Ct (ΔΔCt). The images of the Western Blot, acquired 
through Chemidoc, were analyzed using ImageJ Software. For viability assays in vitro 
survival curves were constructed using Excel software. The Net Growth was calculated 
as the ratio (OD treated - OD T0 / OD untreated control - OD T0) x 100. Viability 
experiments were conducted in octuplicate.  
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4. Results 
 
4.1   Effect of miR-29A, -29B, -29C, -148A, -148B and -152 on the 
expression of DNMTs and ESR1 
 
The silencing effect exerted on the DNMTs and ESR1 mRNAs by the miRs was assessed 
by qRT-PCR analysis performed on cDNA transcribed from RNA extracted from MDA-
MB-231 cells transfected with miR-29A, miR-29B, miR-29C, miR-148A, miR-148B, and 
miR-152, or SCR, 72h post transfection. The analysis showed an effect of miR-29B and 
mir-148A on reducing the DNMT1 and DNMT3A expression (Fig. 11), and 
concomitantly slightly increasing the expression of ESR1, compared to SCR (Fig.12). No 
significant variations were observed for the other miRs on the expression of DNMTs 
and ESR1. 5-Azacitidine was used as an internal control, being a DNA demetylating 
agent able to inhibit the DNMTs. 
 
                                    Fig. 11 DNMTs expression after transfection with miR 29A, 29B, 29C, 148A, 148B, 152 at 72h 
43 
 
 
Fig. 12 ESR1 expression after transfection with miR 29A, 29B, 29C, 148A, 148B, 152 at 72h 
 
4.2 Lack of ER-α  re-expression after miR-29B, miR-148A and miR-
191 transfection 
A possible re-expression of estrogen receptor protein following the observed reduction 
of the expression of DNMT1 and DNMT3A mRNAs was evaluated by Western Blot 
analysis of protein extracts from MDA-MB 231 cells transfected with miR-29B, miR-
148A, and miR-191, which was predicted to target DNMT3A, at 48h and 96h post 
transfection. No expression of estrogen receptor was observed, even in the samples 
treated with 2,5 μM 5-Azacitidine (Fig. 13). 
 
Fig. 13 Western blot after transfection of MDA-MB 231 with miR-29B, miR-148A and miR-191 
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4.3 TNBC cell lines AR/Her2 expression profiling 
Not observing any results in the re-expression of the estrogen receptor, we then 
focused on the unclear role of AR. To test the expression of AR on several triple 
negative breast cancer cell lines a Western Blot was performed, using the prostate 
cancer cell line LNCap as positive control. AR expression was detected in the 
"molecular apocrine" subtype MDA-MB-453, and in the T-47D cell line (Fig.14-15). T-
47D together with MDA-MB-453 were also tested for the expression of Her2 (Fig. 16). 
 
 
                                    Fig. 14 Expression of AR on different TNBC cell lines by Western Blot  
  
 
                                                 Fig. 15 Expression of AR in T-47D breast cancer cell line 
 
Fig. 16 Expression of Her2 in T-47D and MDA-MB-453 breast cancer cell lines compared to SKBr3 control 
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4.4  miRs which are predicted to target AR 
After reviewing various databases for predictive binding site of microRNAs and target 
genes such as TargetScan (http://www.targetscan.org/), miRBase (http:// 
www.mirbase.org/), DIANA LAB (http:// diana.cslab.ece.ntua.gr/) and microRNA.org 
(http:// www.microrna.org/), we finalized the search to the choice of some miRs 
which showed stronger affinity for the 3'-UTR sequence of AR: miRs-7, -9, -15a, -16, -
27a, -27b, -29a, -29b, -29c, -127-3p, -127-5p e -376.  
 
4.5 AR modulation by miRs 
A possible AR modulation worked by miRs-7, -9, -15a, -16, -27a, -27b, -29a, -29b, -29c, 
-127-3p, -127-5p and -376a, was evaluated by Western Blot analysis, performed on 
protein extracts from MDA-MB-453 cells transfected with the miRs mentioned above, 
or SCR at 24, 48 and 72h post transfection. Results showed a general tendency of all 
miRs tested, except miR-15a and miR-16, to down-regulate AR expression at 48h post 
transfection. Conversely, miR-15a and miR-16 showed an up-regulatory effect which 
remained constant for all the three analyzed times.  The same costant effect, but in a 
down regulatory way, was instead explicated by miR-9 (Fig. 17-18-19). 
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Fig. 17 Expression analysis of AR modulated by miRs-7, -15a, -29b, -376 on MDA-MB-453 breast cancer cell line 
 
 
 
 
 
 
 
 
Fig. 18 Expression analysis of AR modulated by miRs-9, -27a, -27b, -29a on MDA-MB-453 breast cancer cell line 
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Fig. 19 Expression analysis of AR modulated by miRs-16, -29c, -127-3p, -127-5p on MDA-MB-453 breast cancer cell 
line 
 
4.6 Silencing of AR is maintained up to 72 h post-transfection 
A silencing kinetic study was performed in order to subsequently investigate the 
mechanism of some drugs. MDA-MB-453 were transfected with siRNAs at two different 
concentrations, 20nM and 50 nM, for 24, 48 and 72 hours. siRNA was effective in 
silencing AR from as early as 24h after transfection, and its effect is maintained up to 
72h post-transfection (Fig. 20).  
 
 
Fig. 20 AR silencing kinetic on MDA-MB-453 cell line 
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The maximum concentration of siRNA, 50 nM, was chosen and used to verify the 
effective silencing also on T-47D cell line (Fig. 21). 
 
 
 
                                                       Fig. 21 AR silencing  on T-47D cell line 
 
 
4.7 Response to Tamoxifen, Metformin and Herceptin treatment 
To evaluate changes in some drug sensitivity after AR silencing both MDA-MB 453 and 
T-47D cell lines were trated with Tamoxifen, or Metformin, or Herceptin, at different 
concentration in agreement with their respective pharmacokinetics, for 24-48-72-120-
144h. About the treatment with Herceptin, T-47D cell line was chosen in function of its 
molecular profile (AR positive, Her2 negative) as an opposite model to MDA-MB 453 
(AR positive, Her2 positive) and its effect was tested by a Bromodeoxyuridine flow 
cytometric assay. For Tamoxifen and Metformin a cell viability assay based on the ATP 
activity measurement was performed. No significant differences in Tamoxifen 
response in both cell lines were observed, except for treatment of MDA-MB-453 at 24h, 
where samples seemed more sensitive when silenced for AR protein (Fig. 22, 24). 
Metformin appeared to act more in samples silenced for AR compared to SCR, in both 
cell lines, , except in MDA-MB-453 at 48h (Fig. 26, 28). The silencing efficiency was 
confirmed by Western Blot analysis for each experiment (Fig. 23, 25, 27, 29).  
49 
 
 
Fig. 22  Net growth analysis after Tamoxifen treatment 5-10 μM at 24-48-72h on MDA-MB-453 cells 
 
 
 
 
 
                                              Fig. 23  Efficiency of silencing transfection on MDA-MB-453 cells 
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Fig. 24 Net growth analysis after Tamoxifen treatment 5-10 μM at 24-48-72h  on T-47D cells 
 
                  
 
                                                Fig. 25  Efficiency of silencing transfection on T-47D cells 
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              Fig. 26 Net growth analysis after Metformin treatment 20-40 mM at 24-48-72h  on MDA-MB-453 cells 
 
 
 
                                                          Fig. 27 Efficiency of silencing transfection on MDA-MB-453 cells 
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              Fig. 28 Net growth analysis after Metformin treatment 20-40 mM at 24-48-72h  on T-47D cells 
 
 
  
                                                           Fig. 29  Efficiency of silencing transfection on T-47D cells 
 
 
53 
 
Herceptin  treatment in MDA-MB 453 cells silenced for AR showed a slight decrease in the 
percentage of proliferating cells, suggesting a response to the drug (Fig. 30, 31). No significant 
changes were observed in T-47D cells (Fig. 33, 34). The silencing efficiency was confirmed by 
Western Blot analysis for each experiment (32, 35). 
 
 
              Fig. 30 Flow cytometric analysis of MDA-MB 453 cells after treatment with Herceptin 1 mM for 120h 
 
 Scr  Scr+Her  siAR  siAR+Her  
% BrdU-  82.0  85.4  71.8  83.9  
% BrdU+  18.7  14.4  27.9  15.8  
 
Tab. 1 Percentage of incorporating BrdU  and non-proliferating MDA-MB-453 cells at 120 hours 
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              Fig. 31  Flow cytometric analysis of MDA-MB 453 cells after treatment with Herceptin 1 mM for 144h 
 
 Scr  Scr+Her  siAR  siAR+Her  
% BrdU-  74.2  80.4  69.7  81.2  
% BrdU+  26.4  18.2  30.1  18.9  
 
Tab. 2 Percentage of incorporating BrdU  and non-proliferating MDA-MB-453 cells at 144 hours 
 
Fig. 32  Efficiency of silencing transfection on MDA-MB-453 cells 
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Fig. 33 Flow cytometric analysis of T-47D  cells after treatment with Herceptin 1 mM for 120h 
 
 Scr  Scr+Her  siAR  siAR+Her  
% BrdU-  83.4 83.9 80.4 80.5 
% BrdU+  16.9 16.0 19.2 19.3 
 
Tab.3  Percentage of incorporating BrdU  and non-proliferating T-47D cells at 120 hours 
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         Fig. 34 Flow cytometric analysis of T-47D  cells after treatment with Herceptin 1 mM for 144h 
 Scr  Scr+Her  siAR  siAR+Her  
% BrdU-  86.5  88.0  86.0  87.6  
% BrdU+  12.5  11.3  13.6  12.6  
 
Tab. 4 Percentage of incorporating BrdU  and non-proliferating T-47D cells at 144 hours 
 
Fig. 35  Efficiency of silencing transfection on T-47D cells 
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5. Discussion 
Breast cancer is a highly heterogeneous disease, characterized by differences both in 
biological aspects, both in the response to the various existing therapies and, 
although in recent decades progresses in hormone therapy have been made, effective 
therapeutic options against TNBCs are still limited. They represent a very aggressive 
tumor subtype, characterized by a reduced overall survival and a diminished risk of 
relapses (131). In particular, the lack of expression of ESR1 is due in the most of cases 
to hypermethylation in CpG islands of the promoter resulting in gene silencing, and 
an altered methylation status of genes is a consequence of the increased expression of 
DNMTs. Furthermore, in breast cancers negative for the expression of ER-α, AR is 
expressed in 10-43% and some studies suggested an increased associated mortality, 
other studies showed that AR can drive tumor progression and might represent a 
therapeutic target for this subtype of breast cancer (62, 64). MiRNAs are non-coding 
RNA that carry out regulation of genes by controlling translation and expression of 
their target mRNAs, and they are involved in a variety of biological processes (80, 81, 
82, 83). A strong correlation between epigenetic and microRNA was observed, 
particularly miRs 29A, 29B and 29C showed complementary sequence with 3'-UTR 
region of DNMTs 3A and 3B, restoring the normal patterns of DNA methylation and 
inducing the re-expression of the hypermethylated gene (123). The identification of 
tumor-specific miRNAs and their molecular targets represent a key step to 
characterize the role of miRNAs in human tumorigenesis and might be important for 
the identification of new therapeutic targets. The understanding of molecular 
mechanisms associated with genes deregulation by miRNAs in human cancer, still 
remains a difficult task to investigate. In fact, although bioinformatics programs can 
help in the prediction of hypothetical target genes, in vitro experimental procedures 
are needed for the validation of molecular targets. Currently many target genes of 
miRNAs have been identified in human cancers, but despite encouraging 
experimental evidences linking miRNAs to cancer biology, little is known about 
cellular and molecular connections in which miRNAs are involved. In fact, the 
understanding is greatly complicated by the ability of miRNAs to target multiple 
molecular pathways, sometimes linked to each other, sometimes with opposite 
functions. Furthermore, miRs can behave as onco-miRNAs or miRNA-tumor 
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suppressors depending on tissue types and specific targets, representing two 
different sides of the same gene (95). All this aspects give rise to a complex regulatory 
network where biological effects and features of a single miRNA not always allow a 
linear explanation. Recently, the potential role of miRNAs as molecules able to restore 
drugs sensitivity when used in combination with pharmaceutical agents has become 
an exciting field to be investigated. One of the advantages of using miRs as 
therapeutic agents is represented by the fact that they are molecules physiologically 
present in the cells and so associated with a hypothetical lower risk of toxicity. 
Furthermore, they are able to induce a phenotype at low concentrations since they 
silence multiple genes simultaneously limiting their amount used to obtain a 
biological effect. Both these features make miRNAs excellent "drugs", as 
demonstrated by their introduction in experimental phase II clinical trials for the 
treatment of viral hepatitis type C (132). Data presented in this thesis had the initial 
aim to investigate the possible role of DNMTs silencing operated by the  miRs-29 
family, and other selected miRs to confer again a normal methylation pattern of ESR1, 
leading to a re-expression of it in TNBCs and thereby restoring a supposed sensitivity 
to Tamoxifen. For this purpose a series of experiments were conducted to analyze the 
possible role of miRs-29 family, identified as first possible candidates and predicted 
in targeting DNMTs, and of miR-148A, miR-148B, miR-152 and miR-191. The selected 
model for the in vitro studies was the TNBC cell line, MDA-MB-231. At 72h post 
transfection, miRs-148A and miR-29B were found to be involved in the reduction of 
the expression of DNMT1 and DNMT3A and in a concomitantly slight increase of 
ESR1 expression compared to the negative control. MiR-148B was seen to decrease 
the expression of DNMT1 correlated to an increase in the expression of ESR1, 
compared to negative control. These data were not confirmed at protein level, as no 
protein expression of estrogen receptor was observed after transfection of cells with 
miRNAs precursors. Consequently the results obtained and on the basis of data in the 
literature, our focus has shifted on Androgen Receptor with the purpose to assess the 
effect of some predicted targeting miRs (miRs-7, -9, -15A, -16, -27A, -27B, -29A, -29B, 
-29C, -127-3p, -127-5p and -376) on its expression. Transfection of cells with 
precursors of selected miRNAs has led to down-regulation of Androgen Receptor at 
protein level at 48h post transfection by all miRs considered, except by miR-15A and 
miR-16 which were observed up-regulating the receptor at every time considered. 
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Finally, assays were conducted to study Tamoxifen, Herceptin and Metformin in order 
to estimate a possible increase of drugs sensitivity after AR silencing in MDA-MB 453 
and T-47D cell lines. In Tamoxifen treatments, cells seemed more sensitive when 
silenced for AR protein only in MDA-MB-453 at 24h post-treatment, might be due to 
activation of molecular pathways in the absence of expression of estrogen receptor. 
Studies on Metformin have confirmed our hypothesis of an increase of drug 
sensitivity due to AR silencing in both cell lines. Analysis of Herceptin assays showed 
how MDA-MB 453 samples silenced for AR have a slight decrease in the percentage of 
proliferating cells, demonstrating a possible increase in the response to treatment. 
These preliminary data provide the basis for further study of the modulation of the 
expression of AR by microRNAs, and how this mechanism can have an impact on 
cancer treatment. Not less important, it will be interesting to understand the 
molecular mechanisms underlying these interactions. Our results, although 
preliminary, might provide further evidence for a possible future use in clinical field 
of these small molecules. 
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